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SLE is an autoimmune disease that is not uncommon in Malaysia. In contrast to Malays and Indians, the Chinese seem to be most
aﬀected. SLE is characterized by deficiency of body’s immune response that leads to production of autoantibodies and failure of
immune complex clearance. This minireview attempts to summarize the association of several candidate genes with risk for SLE
in the Malaysian population and discuss the genetic heterogeneity that exists locally in Asians and in comparison with SLE in
Caucasians. Several groups of researchers have been actively investigating genes that are associated with SLE susceptibility in the
Malaysian population by screening possible reported candidate genes across the SLE patients and healthy controls. These candidate
genes include MHC genes and genes encoding complement components, TNF, FcγR, T-cell receptors, and interleukins. However,
most of the polymorphisms investigated in these genes did not show significant associations with susceptibility to SLE in the
Malaysian scenario, except for those occurring in MHC genes and genes coding for TNF-α, IL-1β, IL-1RN, and IL-6.
1. Introduction
Systemic lupus erythematosus (SLE) is the prototypical
autoimmune disease that is characterized by autoantibody
production, complement activation, and immune complex
deposition leading to diverse clinical manifestations and
target tissue damage. The prevalence of SLE is estimated
to be between 40 and 400 cases per 100,000 individuals [1].
While the precise etiology of SLE still remains vague, genetic
predisposition and environmental and hormonal factors are
deemed to play important roles in its pathogenesis. Severity,
acquisition risk, and clinical manifestations of this disease
can vary by ethnicity, geography, and sex, with a prevalence
that is higher in women during their childbearing ages and
some non-European populations such as African Americans,
Hispanics, and Asians [2, 3].
In Asians, the prevalence of SLE generally falls within
30–50/100,000 individuals. SLE is more frequent among
Chinese communities in Asia than it is in India and tropical
Africa [4]. Malaysia is a multiracial country. In the penin-
sular, the Malays (55.1%), Chinese (24.3%), and Indians
(7.4%) represent the largest ethnic groups. A prevalence of
43/100,000 individuals in Malaysia has been reported [5, 6].
Likewise, Chinese have the highest prevalence of SLE in
Malaysia (57/100,000), followed by Malays (33/100,000) and
Indians (14/100,000) [7, 8]. The overall 5-year and 10-year
survival rates were reported as 82% and 70%, respectively
[5], whereas the overall mortality rate was 20.2% [9]. Renal
involvement is highest among the Malaysian patients [5].
However, the major cause of death in Malaysian SLE patients
was reported to be from infection [9].
Pathogenesis of SLE is associated with functional defi-
ciency of multiple immunologic components, including the
innate immune system, altered immune tolerance mech-
anisms, hyperactivation of T and B cells, reduced ability
of immune complexes and apoptotic cell clearance, and
defects in multiple immune regulatory networks [10]. The
failure of these mechanisms could be due to the influence
of variants within SLE susceptibility genes. To date, many
diﬀerent genes have been found to contribute to disease
susceptibility. In a small proportion of patients (<5%), a
single gene could become the key player for this disease
[11]; however, multiple genes have been implicated in most
patients. It is estimated that at least four susceptibility
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genes or loci are needed for the development of the disease
[12]. The susceptibility genes most extensively studied are
within the major histocompatibility complex (MHC). It is
believed that human leukocyte antigen (HLA) class II gene
variants are very important. The introduction of genome-
wide association studies (GWASs) has not only helped us to
support the findings from previous candidate gene studies,
but also unveiled many other novel genetic loci that may
be important. Candidate genes that have been recently
discovered can be clustered into three main groups: (i) IRF5,
STAT4, TNFAIP3, and TREX1 which are involved in innate
immune response including TLR/interferon signalling path-
way; (ii) HLA-DR, PTPN22, PDCD1, LYN, BLK, and BANK1
which are involved in immune signal transduction of B, T,
and antigen-presenting cells; (iii) C2, C4, FCGRs, CRP, and
ITGAM which are involved in immune complex clearance
mechanism [13, 14].
The genetic information obtained fromGWAS has allow-
edmany researchers to investigate specific variants for partic-
ular genetic loci using a variety of approaches such as RFLP-
PCR, tetra-primer ARMS-PCR, and real-time genotyping
PCR. This in turn has enabled the replication of these exper-
iments and confirmed those associated polymorphisms with
SLE in diﬀerent populations. Genetic heterogeneity is com-
mon among populations in SLE, especially between Cau-
casians and Asians. For instance, PTPN22, which demon-
strated significant association with SLE in Caucasians, was
not found to be associated with some ethnicities in Asia [15].
The identification of genetic heterogeneity may enhance our
understanding of mechanisms that lead to SLE pathogenesis
in certain populations and subsequently may permit more
precise diagnosis, prognosis, and treatment for the patients.
In Malaysia, researchers have been actively looking into
the genetic risk factors of SLE in the multiracial population
for the past 15 years. These eﬀorts have generated a consid-
erable amount of data that have been useful contributions to
enriching global statistics and knowledge of SLE. PCR-based
methods were mainly used in these studies. In this paper,
the association of several candidate susceptibility genes with
SLE in Malaysian population will be discussed and sum-
marized (Table 1). In addition, genetic heterogeneity in
SLE susceptibility observed in diﬀerent ethnicities will be
discussed.
2. Candidate Genes
2.1. Major Histocompatibility Complex Genes. The major
histocompatibility complex (MHC), which contains human
leukocyte antigen (HLA) genes, is a large genomic region
located on chromosome 6. HLA antigens and genes have
long been associated with SLE, and this can be dated back
to 1971, when Grumet et al. [33] reported a possible re-
lationship. Of the several classes of HLA, HLA class II
genes seem particularly important in SLE. They encode cell-
surface antigen-presenting proteins that present antigens
to T cells and in turn stimulate the multiplication of T-
helper cells and production of antibodies by B cells. HLA
class II genes have also been associated with the presence
of certain autoantibodies such as anti-Sm, anti-Ro, anti-
La, anti-nRNP, and anti-DNA antibodies, which have been
useful biomarkers in SLE diagnosis. HLA-DR2 has been
reported to be consistently associated with SLE in both
Caucasian and Asian populations [34, 35]. HLA class III
genes, particularly those encoding complement components
C2 and C4, may also confer increased risk for SLE in diﬀerent
ethnicities
In Malaysia, Azizah et al. [16] reported significant asso-
ciation of HLA-DR2, -DQB1∗0501, and -DQB1∗0601 with
SLE in Malays. A significant positive association of DR2 and
DQB1∗0501 with renal involvement and DR8 with alopecia
in Malays was also described in their study. For the investi-
gation of the role of HLA genes in autoantibody expression,
they found significant association of DQB1∗0601 with anti-
Sm/RNP, DR2 with anti-Ro/La, and DR2, DRB1∗0501 and
∗0601 with anti-dsDNA. The same group of researchers
also carried out similar study on Chinese population
and suggested that DQB1∗0102, DQB1∗0501, ∗0601, and
DPB1∗0901 were significantly associated with SLE [17].
Clinically, a strong association of DR2 and DQA1∗0301 with
renal involvement and DQA1∗0102 with alopecia was re-
ported. In contrast toMalays, DQA1∗0102 and DQA1∗0301
were observed to be strongly associated with anti-Ro/La and
anti-dsDNA, respectively, in Chinese. Earlier on, Doherty
et al. [18] reported that HLA-DRw15 and DQw1 were
observed to be significantly associated with SLE among
Southern Chinese in Malaysia and most prevalent in patients
with lupus nephritis and cutaneous manifestation.
A recent comprehensive study conducted byMohd-Yusuf
and coworkers [19] in Malaysia revealed that HLA A∗1101,
1102, DRB5∗01-02, DQB1∗05, DRB3∗0101, 0201, 0202,
0203, 0301, and DQB1∗0301, 0304 were significantly asso-
ciated with SLE in Malaysians. In addition, DRB1∗0701
and DRB4∗0101101, 0102, 0103 alleles were significantly
increased in the Malay SLE patients, whilst DRB1∗1601-
1606 (DR2 subtype) and DRB5∗0101, 0102, 0201, 0202,
0203 alleles were significantly higher in Chinese SLE patients.
The investigation revealed that these two diﬀerent sets of DR
alleles may be specific and representative for the two ethnic
groups in this SLE cohort and that DQB1∗05 could be the
common HLA susceptibility allele in the Malaysian SLE pop-
ulation.
2.2. Complement Components. The complement system is
mainly involved in innate immunity, whereby it helps to
remove cellular debris from foreign and apoptotic cells.
The links between complement system activity with SLE
have been reported since the 1980s. Mutant C4 genes have
been mostly reported in Caucasian families, but are still un-
common in other populations. Apart from Caucasians, the
presence of C4A null allele (C4aQ0) was also observed in
Chinese and Japanese with SLE by Dunckley et al. [36]. In
the Malaysian scenario, none of the mutations located at
exons 13, 20 and 29 of C4 gene, as well as the null alleles,
was found to be significantly associated with SLE [20]. The
same situation was also observed in Malaysian Southern
Chinese by Doherty et al. [18]. However, a synergistic eﬀect
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of C4 deletions and HLA-DRw15 in conferring disease
susceptibility was detected.
The other complement component of particular impor-
tance in SLE is C1q. Individuals having a congenital genetic
deficiency of C1q gene could develop SLE-like symptoms
at more than 90% prevalence [37, 38]. Various mutations
in C1q have been reported, including nonsense mutations,
missense mutations and single nucleotide polymorphisms
(SNP). It is conceivable that these may lead to failures in
the synthesis of intact C1q molecules leading to abnormal
immune responses. While C1q deficiency was reported to be
associated with SLE in Turkish andMexican subjects [39, 40],
no association was observed between any of themutations [at
C1qA-Gln186 (C > T), C1qB-Gly15 (G > A), C1qB-Arg150
(C > T), C1qCGly6, (G > A), and C1qC-Arg41 (C > T)], or
SNPs [at C1qAGly70 (G/A), and C1qC-Pro14 (T/C)] within
C1q and SLE in the Malaysia [21].
2.3. Tumour Necrosis Factor . Tumour necrosis factor (TNF)
genes are situated at the short arm of chromosome 6.
TNF proteins are a group of low-molecular-weight cytokines
that mediate inflammation processes. TNF-alpha (TNF-α)
protein, also known as cachectin, has been frequently investi-
gated. It plays an important role in the regulation of immune
cells, stimulation of apoptotic cell death, and induction of
inflammation. Cytokine imbalances are believed to be drivers
of certain autoimmune diseases, including SLE. The first bi-
allelic TNF-α gene polymorphism was reported by Wilson et
al. [41], which involved a single base change from G to A at
the position -308 in the promoter region of the gene. Ameta-
analysis study revealed that the 308-A/G functional promoter
polymorphism association was inconsistent. However the
risk genotype A/A and risk allele A were associated with
SLE in European populations but not in Asian or African
populations [42]. The other member of TNF family is TNF-
beta (TNF-β), known as lymphotoxin. The biallelic poly-
morphism in intron 1 of TNF-β gene is believed to influence
TNF-α production and has been associated with SLE in both
Caucasian and Asian populations [43–45].
Risk allele A of TNF-α −308 was associated with SLE
in Malaysian cohorts as reported by Azizah et al. [22] and
Chua et al. [23], in conjunction with a significant increased
frequency of A/G heterozygotes in patients. The TNF-β
+252 polymorphism in intron 1 did not feature in SLE sus-
ceptibility [23].
2.4. Fc Gamma Receptors. Fc gamma receptors (FcγRs) are
present on the surface of most eﬀector cells of the immune
system and involved in mediation of phagocytosis, immune
complex clearance, antibody-dependent cell-mediated cyto-
toxicity and stimulation of inflammatory cells [46].
FcγRIIa is the most widely distributed member of FcγR,
and FcγRIIA gene may occur in two allelic forms that can
cause single amino acid residue modification at position
131. FcγRIIa-R131 has a relatively lower aﬃnity for human
IgG2 that causes less ability to process and clear immune
complexes eﬀectively. Thus it was suggested as a disease
susceptibility factor for SLE, as observed in a meta-analysis
that involved European, African, and Asian populations [47].
However many studies actually did not show association
between polymorphism of FcγRIIA and SLE susceptibility
in their populations [48], including Malays and Chinese in
Malaysia [24].
FcγRIII is encoded by two distinct but highly homolo-
gous genes: FcγRIIIA and FcγRIIIB. A SNP (T to G substi-
tution) in FcγRIIIA that results in a valine (V) substitution
for phenylalanine (F) at amino acid residue position 158 has
been correlated with SLE in Asians [35]. As for FcγRIIIB,
the polymorphism may occur as neutrophil antigen 1 (NA1)
or 2 (NA2). Study by Yap and coworkers [7] showed no
association between FcγRIIIB-NA polymorphism and SLE
in Malay and Chinese patients in Malaysia. This was in
agreement with other reports in Caucasian SLE patients.
They were also able to detect a Chinese SLE patient with NA-
null, which is a consequence of a FcγRIIIB gene deficiency or
deletion.
2.5. T-Cell Receptors. CD28 and CTLA-4 are receptors on T-
cell surfaces that have opposite eﬀects on T cells. CD28 is a
costimulatory molecule which is responsible for T-cell pro-
liferation, cytokine production, and the prevention of T-cell
anergy [49], whereas CTLA-4 maintains the immune res-
ponse at physiological level by regulating the activity of CD28
and T-cell activation.
Few studies have been carried out to investigate the asso-
ciation of CD28 gene polymorphism with SLE susceptibility.
A study performed on the Malaysian population demon-
strated no association between CD28 IVS3 +17T/C SNP
and SLE susceptibility, although the frequency of T allele
and its corresponding homozygous was the highest among
the population [25]. In contrast to CD28, there have been
more reports of the association of CTLA-4 polymorphisms
with SLE, both in Caucasians and Asians. CTLA-4 promoter
(−1722 T/C) polymorphism and (+49 A/G) polymorphism
from exon-1 were found to have their TC and GG genotypes,
respectively, being significantly associated with SLE in Asian
populations [35, 50]. However, polymorphisms in CTLA-
4 gene (+49A/G at exon 1, −1722T/C, −1661A/G and
−318C/T at promoter sites and +6230A/G in 3′-untranslated
region) were not reported to be important in Malaysian SLE
patients [26].
2.6. Interleukins. Interleukins are a group of cytokines, the
majority of which are secreted by helper T cells, monocytes,
macrophages, dendritic cells, natural killer cells, and B cells.
They are mainly involved in promoting the development and
diﬀerentiation of T and B cells and activation of natural killer
cells.
Interleukin-1 (IL-1) is a polypeptide encompassing IL-1
alpha (IL-1α) and IL-1 beta (IL-1β). IL-1 gene is located on
chromosome 2, and genes encoding IL-1α and IL-1β are in
close proximity to each other. The defective production of IL-
1 has been implicated in development of SLE since 1983 [51].
However, not many studies have been conducted to investi-
gate the association between IL-1 gene polymorphisms and
susceptibility to SLE. According to Chua et al. [27], SLE
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patients in Malaysia are susceptible to IL-1β −511 C/T
polymorphism, with the C allele and its corresponding
homozygous exhibiting a higher risk to SLE. These findings
diﬀered from a report by Parks et al. [52] that showed T
allele had more potential to confer risk of SLE in African
Americans. In Taiwan, no association between IL-1β −511
C/T polymorphism and SLE was observed [53]. In a similar
study carried out by Chua and coworkers [27], a significant
correlation of another IL-1β polymorphism (+3954 E1/E2 in
exon 5) with SLE susceptibility in Malaysian population was
noted, with E1 allele rather than the E2 at higher frequency
among patients. This was also the case in Columbian SLE pa-
tients but not in the Taiwanese [53, 54].
The secretion and activity of IL-1 are tightly counter-
balanced by IL-receptor antagonist (IL-1ra), which competi-
tively binds to the same receptor as IL-1. IL-1RN gene, which
encodes IL-1ra, is also situated on chromosome 2. The dys-
regulation of IL-1 production by IL-1ra will cause abnormal
inflammatory activity that leads to subsequent tissue da-
mage, which is the characteristic pathogenesis of SLE. In as
much as IL-1ra may contribute to the occurrence of SLE,
many studies have been done to investigate the association
of polymorphisms in IL-1RN gene with SLE susceptibility.
Polymorphism in IL-1ra is always characterised by variable
numbers of an 86-bp tandem repeat in the intron 2 that may
functionally aﬀect three potential protein binding sites: an α-
interferon silencer A, a β-interferon silencer B, and an acute-
phase response element [55]. The first study to correlate this
polymorphism with SLE susceptibility was done on Cau-
casians in 1994, and carriage of IL-1RN∗2 was reported to
be associated with severity rather than susceptibility to SLE
[56]. In Malaysia, however, the risk allele associated with SLE
susceptibility in SLE patients was IL-1RN∗1 instead. The IL-
1RN∗2 allele displayed an inverse association [28].
Interleukin-4 (IL-4) is secreted by T-helper type-2 cells
and responsible for proliferation and diﬀerentiation of B
and T cells, as well as production of antibodies. IL-4 gene
is located on human chromosome 5, and the study of the
impact of its polymorphisms on SLE susceptibility is not as
popular as other candidate genes. An IL4 haplotype −590C/
−33C/9241G/14965C was significantly associated with SLE
in Taiwan Chinese population [57]. Another study in Taiwan
revealed the association of IL-4−590T/C and intron 3 VNTR
(variable number of tandem repeats) poly-morphisms with
the presence of certain clinical manifestations in SLE patients
[58]. In the Malaysian cohort that was studied, the VNTR
variants within intron 3 of IL-4 gene were not associated with
SLE susceptibility [8].
Interleukin-6 (IL-6) gene, located on chromosome 7, is
another interleukin gene of interest that has been studied and
associated with the susceptibility of SLE. IL-6 promoter poly-
morphism (−174G/C) is commonly investigated as a risk
factor in SLE.While a study onMalaysian population found a
significant correlation between homozygous G genotype and
SLE susceptibility, none of the studies in Taiwan, Iran, and
Portugal reported the association of this polymorphism with
SLE in their populations [29, 59–61].
Interleukin-10 is also believed to play an important role
in the pathogenesis of SLE. Various polymorphisms in IL-10
promoter region have been reported to display significant
association with SLE susceptibility [62–64]. An earlier study
reported that the IL10.G microsatellite alleles in IL-10 pro-
moter region had significantly higher frequency in Caucasian
SLE patients [64]. A study investigating the relationship of
three SNPs in IL-10 gene promoter (−1082G > A,−824C >
T, and −597C > A) with SLE susceptibility in Malaysian
population revealed that haplotype frequencies rather than
genotypes or alleles were more important [30].
2.7. Other Genes. The role of angiogenic-converting enzyme
(ACE) gene I/D dimorphism in susceptibility to SLE in the
Malaysian population was illustrated by Lian and coworkers
[31]. ACE gene, located on the q arm of chromosome
17, produces protein which is an important player in the
renin-angiotensin system and kallikrein-kininogen system
[65]. Dysregulation of ACE could lead to vascular damage,
particularly in kidneys of SLE patients. In that study, no
significant diﬀerence was observed in the distribution of I
and D alleles between cases and healthy controls although
ID heterozygote did show significant association with SLE
[31]. This finding was in accordance with what was reported
in African-American and European-American populations
[66] but contradicted those in Japanese and Slovakian pop-
ulations, whereby I and D alleles were found, to be sig-
nificantly associated with SLE, respectively [66, 67].
Polymorphisms at position 28 of the regulated on acti-
vation, normal T cell expressed and secreted (RANTES) gene
promoter region and position 801 in 3′ UTR of stromal cell-
derived factor 1 (SDF-1) gene were also analysed by Lian et al.
[32]. Again, both polymorphisms did not show significant
association with SLE in Malaysia and similar observations
were also reported in Mexican and Han Chinese populations
[68–70].
3. Conclusion
Most studies conducted in Malaysian SLE patients did not
exhibit significant association of the candidate genes with
susceptibility, safe for a few which are within the human
MHC. There are several pertinent reasons for these findings.
Firstly, this could be due to smaller sample sizes as it is often
diﬃcult to obtain large numbers of SLE patients within a
medical centre or hospital within a relatively short period
of time when such studies are undertaken. So far, there has
yet to be a long term or longitudinal national study on this
enigmatic disease. The second reason may be that given the
complexity of SLE and the dynamic nature of the disease,
there may well be diﬀerent sets of genes and biological
players that assume various roles during the precipitation
and pathogenesis of SLE from predisposition to actual onset
and resultant progression. The genetic heterogeneity evident
in diﬀerent SLE patients of various ethnicities could also be
attributed to the inheritance of diﬀerent ancestral genotypes
that impact upon the development and/or progression of
this disease [13]. Gene-gene and gene-environment inter-
actions could also confer diﬀerences in susceptibility to
or be protective against a particular disease in diﬀerent
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populations or ethnic groups. It is hoped that with larger and
better defined patient sets and appropriate controls, more
comprehensive genetics and systems biology approaches,
and better technologies, we will be able to gain a better
understanding of SLE and insight into ways of managing this
most enigmatic and challenging of autoimmune diseases.
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